A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/3/2016
Start Date:February 2012
End Date:September 2014

Use our guide to learn which trials are right for you!

A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

This open-label, parallel group study will evaluate the pharmacokinetics and safety of
trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and normal or
reduced hepatic function. Patients will receive trastuzumab emtansine intravenously on Day 1
of each 3-week cycle. Anticipated time on study treatment is until disease progression or
unacceptable toxicity occurs.


Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically or cytologically documented invasive metastatic breast cancer

- Human epidermal growth factor receptor 2 (HER2) -positive disease

- Adequate bone marrow and organ function (other than hepatic dysfunction allowed by
protocol)

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Left ventricular ejection fraction >/=50%

- Normal hepatic function, or mild to moderate hepatic impairment (Child-Pugh Class A
or B)

Exclusion Criteria:

- History of Grade >/=3 infusion reaction, hypersensitivity reaction, or pneumonitis in
response to trastuzumab

- Investigational therapy or any other anticancer therapy treatment

- Previous treatment with trastuzumab emtansine

- Brain metastases that are untreated or symptomatic or require therapy to control
symptoms or any radiation, surgery or other therapy to control symptoms from brain
metastases within 1 month of the first study treatment

- History of other malignancy within the last 5 years, except for appropriately treated
carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer,
or other cancers with a similar outcome as those mentioned above

- Current peripheral neuropathy of Grade >/=2

- Child-Pugh Class C hepatic impairment

- Encephalopathy >/= Grade 2

- For patients with normal hepatic function: history of drug or alcohol addiction or
history of hepatitis B and/or hepatitis C

- Active hepatitis A, B and/or C

- Current unstable ventricular arrhythmia requiring treatment

- History of symptomatic CHF (NYHA Classes II-IV)

- History of myocardial infarction or unstable angina within 6 months of enrollment

- History of a decrease in LVEF to<40% or symptomatic CHF with previous trastuzumab
treatment

- Pregnant or lactating women

- Known HIV infection
We found this trial at
5
sites
2616
mi
from 98109
Fort Myers, FL
Click here to add this to my saved trials
1933
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
2188
mi
from 98109
Ottawa,
Click here to add this to my saved trials
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials